Influence of department volume on survival for ovarian cancer: results from a prospective quality assurance program of the Austrian Association for Gynecologic Oncology
- PMID: 19258949
- DOI: 10.1111/IGC.0b013e31819915cb
Influence of department volume on survival for ovarian cancer: results from a prospective quality assurance program of the Austrian Association for Gynecologic Oncology
Abstract
Objective: The Austrian Association for Gynecologic Oncology initiated in 1998 a prospective quality assurance program for patients with ovarian cancer. The aim of this study was to evaluate factors predicting overall survival especially under consideration of department volume.
Methods: All Austrian gynecological departments were invited to participate in the quality assurance program. A questionnaire was sent out that included birth date, histology, date of diagnosis, stage, and basic information on primary treatment. Description of comorbidity was not requested. Patient life status was assessed in a passive way. We did record linkage between each patient's name and birth date and the official mortality data set collected by Statistics Austria. No data were available on progression-free survival. Patients treated between January 1, 1999 and December 31, 2004 were included in the analysis. Mortality dates were available to December 31, 2006. Data were analyzed by means of classical statistical methods. Cut-off point for departments was 24 patients per year.
Results: A total of 1948 patients were evaluable. Approximately 75% of them were treated at institutions with fewer than 24 new patients per year. Patient characteristics were grossly similar for both department types. Multivariate analysis confirmed established prognostic factors such as International Federation of Gynecologists and Obstetricians (FIGO) stage, lymphadenectomy, age, grading, and residual disease. In addition, we found small departments (<24 patients per year) to have a negative effect on overall survival (hazards ratio, 1.38: 95% confidence interval, 1.2-1.7; and P < 0.001).
Conclusions: The results indicate that in Austria, rules prescribing minimum department case load can further improve survival for patients with ovarian cancer.
Similar articles
-
Influence of department volume on cancer survival for gynaecological cancers--a population-based study in Tyrol, Austria.Gynecol Oncol. 2006 Nov;103(2):527-34. doi: 10.1016/j.ygyno.2006.03.044. Epub 2006 May 26. Gynecol Oncol. 2006. PMID: 16730055
-
Long-term significance of urinary neopterin in ovarian cancer: a study by the Austrian Association for Gynecologic Oncology (AGO).Ann Oncol. 2016 Sep;27(9):1740-6. doi: 10.1093/annonc/mdw248. Epub 2016 Jun 29. Ann Oncol. 2016. PMID: 27358381
-
Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients.J Natl Cancer Inst. 2006 Feb 1;98(3):172-80. doi: 10.1093/jnci/djj019. J Natl Cancer Inst. 2006. PMID: 16449677
-
FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina.Semin Surg Oncol. 1994 Jan-Feb;10(1):31-46. doi: 10.1002/ssu.2980100107. Semin Surg Oncol. 1994. PMID: 8115784 Review.
-
Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.Rev Colomb Obstet Ginecol. 2024 Jun 14;75(1):4094. doi: 10.18597/rcog.4094. Rev Colomb Obstet Ginecol. 2024. PMID: 39013199 Free PMC article. English, Spanish.
Cited by
-
The Relevance of Gynecologic Oncologists to Provide High-Quality of Care to Women with Gynecological Cancer.Front Oncol. 2016 Jan 14;5:308. doi: 10.3389/fonc.2015.00308. eCollection 2015. Front Oncol. 2016. PMID: 26835417 Free PMC article. Review.
-
The landscape of ovarian cancer surgery in Italy: Data from PNE.Eur J Obstet Gynecol Reprod Biol X. 2025 Mar 27;26:100383. doi: 10.1016/j.eurox.2025.100383. eCollection 2025 Jun. Eur J Obstet Gynecol Reprod Biol X. 2025. PMID: 40264966 Free PMC article.
-
Optimization of surgical treatment of advanced ovarian cancer: a Spanish expert perspective.Clin Transl Oncol. 2019 May;21(5):656-664. doi: 10.1007/s12094-018-1967-4. Epub 2018 Oct 30. Clin Transl Oncol. 2019. PMID: 30377941
-
Enhancing ovarian cancer care: a systematic review of guideline adherence and clinical variation.BMC Public Health. 2019 Mar 12;19(1):296. doi: 10.1186/s12889-019-6633-4. BMC Public Health. 2019. PMID: 30866891 Free PMC article.
-
Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study.BMC Cancer. 2021 Jun 27;21(1):738. doi: 10.1186/s12885-021-08507-y. BMC Cancer. 2021. PMID: 34176478 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical